

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016731 A3

(51) International Patent Classification⁷: **C12N 5/00**,
A01N 63/00, A61K 48/00

(21) International Application Number:
PCT/IL2003/000681

(22) International Filing Date: 17 August 2003 (17.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/404,137 19 August 2002 (19.08.2002) US
60/404,145 19 August 2002 (19.08.2002) US
152904 17 November 2002 (17.11.2002) IL
PCT/IL03/00062 23 January 2003 (23.01.2003) IL
PCT/IL03/00064 26 January 2003 (26.01.2003) IL
60/452,545 7 March 2003 (07.03.2003) US

(71) Applicant (for all designated States except US):
GAMIDA-CELL LTD. [IL/IL]; 5 Nahum Hafzadi
Street, Ofer Building, Givat Shaul, 95 484 Jerusalem (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PELED, Tony**
[IL/IL]; 19 Bareket Street, 90 805 Mevaseret Zion (IL).
TREVES, Avi [IL/IL]; 10 Carmel Street, 90 805 Mevaseret
Zion (IL). **ROSEN, Oren** [IL/IL]; 14 Moshe Kol Street,
93 715 Jerusalem (IL).

(74) Agent: **G. E. EHRLICH (1995) LTD.**; 11 Menachem Be-
gin Street, 52 521 Ramat Gan (IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
10 September 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CUL-
TURES

(57) Abstract: Ex-vivo methods of expanding hematopoietic stem cells of hematopoietic mononuclear cells that comprise a major
fraction of hematopoietic committed cells and a minor fraction of hematopoietic stem and progenitor cells, expanded populations of
hematopoietic stem cells obtained thereby and their uses are disclosed



WO 2004/016731 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL03/00681

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00; A01N 63/00; A61K 48/00

US CL : 435/377, 384, 385, 386, 387; 424/93.2, 93.21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/377, 384, 385, 386, 387; 424/93.2, 93.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EAST, CAPLUS, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHIMAKURA, Y. et al. Murine Stromal Cell Line HESS-5 Maintains Reconstituting Ability of Ex Vivo-Generated Hematopoietic Stem Cells from Human Bone Marrow and Cytokine-Mobilized Peripheral Blood. Stem Cells. 2000, Volume 18, pages 183-189.	1-200
A	BRANDT, J.E. et al. Ex Vivo Expansion of Autologous Bone Marrow CD34+ Cells with Porcine Microvascular Endothelial Cells Results in a Graft Capable of Rescuing Lethally Irradiated Baboons. Blood. 01 July 1999, Volume 94, No. 1, pp. 106-113.	1-200
A	PELED, T. et al. Regulation of Long-Term Expansion of Hemopoietic Stem/Progenitor cells (HPC) by Intracellular Copper Content. Blood. 16 November 2000, Volume 96, Part 1, pp. 776a-777a.	1-200
A	VERLINDEN, L. et al. Interaction of Two Novel 14-Epivitamin D3 Analogs with Vitamin D3 Receptor-Retinoid X Receptor Heterodimers on Vitamin D3 Response Elements. Journal of Bone and Mineral Research. 2001, Volume 16, No. 4, pp. 625-638	1-200



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 February 2004 (19.02.2004)

Date of mailing of the international search report

27 JUL 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Deborah Crouch, Ph.D.

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HMAMA, Z. ET AL. 1-Alpha, 25-Dihydroxyvitamin D3-Induced Myeloid Cell Differentiation is Regulated by a Vitamin D Receptor-Phosphatidylinositol 3-Kinase Signalling Complex. Journal Experimental Medicine. 06 December 1999, Volume 190, No. 11, pp. 1583-1594.	1-200
A	JIANG, B-H. et al. Phosphatidylinositol 3-Kinase Signaling Mediates Angiogenesis and Expression of Vascular Endothelial Growth Factor in Endothelial Cells. Proceedings National Academy of Sciences (USA). 15 February 2000, Volume 97, No. 4, pp. 1749-1753.	1-200
A	BERADI, a.c. et al. Individual CD34+cd838lowCD19-CD10- Progenitor Cells From Human Cord Blood Generate B Lymphocytes and Granulocytes. Blood. 15 May 1997, Volume 89, No. 10, pp. 3554-3564.	1-200
A	HAUNG, Z.L. et al. Differentiation of Human U937 Promonocytic Cells is Impaired by Moderate Copper Deficiency. Experimental Biology and Medicine. 2001, Volume 226, No. 3, pp. 222-228.	1-200
A	KANG, H-J. et al. Retinoic Acid and Its Receptors Repress the Expression and Transactivation Functions of Nur77: A Possible Mechanism for the Inhibition of Apoptosis by Retinoic Acid. Experimental Cell Research. 2000, Volume 256, pp. 545-554.	1-200
A	DEFACQUE, H. et al. Expression of Retenoid X Receptor-Alpha is Increased Upon Monocytic Cell Differentiation. Biochemical and Biophysical Research Communications. 1996, Volume 220, pp. 315-322.	1-200
A	SCHMETZER, H.M. et al. Effect of GM-CSF, 1,25-Dihydroxycholecalciferol (Vit. D) and All-Trans-Retinoid Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro. Hematology. 1997, Volume 2, pp. 11-19.	1-200
A	LEE, Y..Y. et al. Effect of Vitamin D Analog, EB1089, on Hematopoietic Stem Cells from Normal and Myeloid Leukemic Blasts. Leukemia. 1996, Volume 10, pp. 1751-1757.	1-200
A	MEHTA, K. et al. Retinoid-Mediated Signaling Pathways in CD38 Antigen Expression in Myeloid Leukemia Cells. Leukemia and Lymphoma. 1999, Volume 32, Issue 5/6, pp. 441-449.	1-200
A	CAKIR-KIEFER, C. et al. Kinetic Competence of the cADP-Ribose-CD38 Complex as an Intermediate in the CD38/NAD(+) Glycohydrolase-Catalysed Reactions: Implication for CD38 Signalling. Biochemical Journal. 2001, Volume 358, pp.399-406.	1-200
A	RATAJCZAK, M. Z. et al. Effect of basic (FGF-2) and acidic (FGF-1) Fibroblast Growth Factors on Early Hematopoietic Cell Development. British Journal of Hematology. 1996, Volume 93, pp. 772-782.	1-200
A	JOHNSON, A.T. et al. Synthesis and Biological Activity of High-Affinity Retinoic Acid Receptor Antagonists. Bioorganic and Medicinal Chemistry. July 1999, Volume 7, No. 7, pp. 1321-1338.	1-200